• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Clark Robert (Amendment)

    12/8/23 5:28:13 PM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IXHL alert in real time by email
    SEC FORM 3/A SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Clark Robert

    (Last) (First) (Middle)
    221 DOSORIS LANE

    (Street)
    GLEN COVE NY 11542

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    11/28/2023
    3. Issuer Name and Ticker or Trading Symbol
    Incannex Healthcare Inc. [ IXHL ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    12/06/2023
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) 11/28/2023 05/31/2024 Common Stock, par value $0.0001 25,000 $65.75 D
    Stock Option (right to buy) 11/28/2023 05/31/2024 Common Stock, par value $0.0001 25,000 $98.63 D
    Explanation of Responses:
    Remarks:
    This Amendment to Form 3 is to correct a typographical error regarding the amount of derivative securities beneficially owned by Mr. Clark at November 28, 2023. There are no non-derivative securities beneficially owned.
    /s/ Robert Clark 12/08/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IXHL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IXHL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IXHL
    Leadership Updates

    Live Leadership Updates

    See more
    • Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates

      NEW YORK and MELBOURNE, Australia, May 15, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported fiscal second quarter financial results and provided business highlights for the quarter ended March 31, 2025. "The third quarter of 2025 represents a pivotal period of progress for Incannex as we continue to execute on our IHL-42X development program," said Joel Latham, President and CEO of Incannex. "With the rapid completion of Phase 2 enrollment in the Phase 2/3 RePOSA, recent positive and confirmatory PK and safety clinical results, and the addition of

      5/15/25 8:00:00 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

      Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew OSA Clinical Advisory Board Announced; Appoints Dr. Alison Wimms, Representing ResMed NEW YORK and MELBOURNE, Australia, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported fiscal second quarter financial results and provided business highlights for the quarter ended December 31, 2024. "Patients with obstructive sleep apnea need new and convenient therapeutic options to manage this serious, chroni

      2/14/25 7:30:00 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

      NEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed. Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine (Sleep Medicine) and Bachelor of Science degrees from the University of Sydney. "Incannex's

      2/4/25 9:15:00 AM ET
      $IXHL
      $RMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments

    $IXHL
    Financials

    Live finance-specific insights

    See more
    • Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement

      MELBOURNE, Australia, July 27, 2022 /PRNewswire/ -- Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ:IXHL), ('Incannex' or the 'Company'), is pleased to provide its quarterly activities report and appendix 4C for the period ended 30 June 2022. Incannex is undertaking a multitude of U.S. Food and Drug Administration ('FDA') programs for cannabinoid pharmaceutical products and psychedelic medicine therapies administered by health professionals. Cannabinoid IHL-42X: positive phase 2a clinical trial results in patients with obstructive sleep apnoea In June 2022, Incannex announced positive results from full analysis of its phase 2 clinical trial o

      7/27/22 7:55:00 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Quarterly Activities Report and Appendix 4C Cash Flow Statement

      Highlights: Positive phase 2a clinical trial results for IHL-42X with 60% of trial participants experiencing at least a 55% reduction in the Apnoea Hypopnea Index ('AHI') 20% of IHL-42X clinical trial participants experienced a reduction in AHI of greater than 80% completes comprehensive in vivo study on the neuroprotective capability of IHL-216A with results being analysed to be released within 2-3 weeks treatment commences in the phase 2a clinical trial to assess psilocybin and specialised psychotherapy for the treatment of generalised anxiety disorder initiates a second clinical psychedelic therapy program in a leading-edge academic field of virtual reality (VR) exposure response therapy

      4/28/22 7:55:00 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IXHL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Barbato Luigi M. was granted 100,476 shares (SEC Form 4)

      4 - Incannex Healthcare Inc. (0001873875) (Issuer)

      10/24/24 4:49:53 PM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Barbato Luigi M.

      3 - Incannex Healthcare Inc. (0001873875) (Issuer)

      10/24/24 4:48:47 PM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Swan Joseph increased direct ownership by 5,079% to 51,793 units (SEC Form 5)

      5 - Incannex Healthcare Inc. (0001873875) (Issuer)

      8/2/24 6:10:16 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IXHL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance

      NEW YORK and MELBOURNE, Australia, May 29, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage pharmaceutical company developing novel combination therapies, today announced that the Phase 3 component of the RePOSA clinical trial will proceed. The U.S. Food and Drug Administration (FDA) previously reviewed and authorized the protocol to proceed under the Company's Investigational New Drug (IND) application. The study will evaluate the efficacy and safety of IHL-42X, Incannex's lead asset for the treatment of obstructive sleep apnea (OSA)—a condition affecting an estimated one billion people globally with no approved oral pharmaceutical therapy. With the FDA

      5/29/25 7:30:00 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results

      MELBOURNE, Australia and NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, today announced that it has entered into a binding agreement to cancel the remaining 172 million Series A Warrants issued under a previous financing arrangement contingent upon Incannex paying the Series A Warrant holders a cancellation payment of up to $12.2 million. When combined with the earlier tranche canceled earlier this month, this agreement will result in the elimination of up to 347.2 million shares from potential future dilution, pending final execution. This strat

      5/28/25 7:00:00 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution

      NEW YORK and MELBOURNE, Australia, May 20, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company pioneering the development of combination drug therapies, today announced the successful completion of a $16.7 million gross proceeds capital raise through its at-the-market (ATM) facility. $12.5 million of these proceeds will be used to cancel up to 50.4% of the Series A Warrants previously issued as part of a prior financing agreement. This strategic initiative significantly reduces potential future dilution attributable to the Series A Warrants, with up to 5,841,038 of these warrants eligible for cancell

      5/20/25 7:30:00 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IXHL
    SEC Filings

    See more
    • Incannex Healthcare Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Incannex Healthcare Inc. (0001873875) (Filer)

      5/29/25 7:45:23 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Incannex Healthcare Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Incannex Healthcare Inc. (0001873875) (Filer)

      5/28/25 7:15:26 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Incannex Healthcare Inc.

      424B5 - Incannex Healthcare Inc. (0001873875) (Filer)

      5/28/25 6:36:01 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care